━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TECHNOLOGY TRANSFER PACKAGE
P-01
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**TECHNICAL READINESS**: T2-CONDITIONAL
**TRANSFER POSTURE**: READY_FOR_TECHNICAL_EVALUATION
**COMMERCIAL STATE**: UNCONTACTED
**VALIDATION**: VALID

**ONE-LINE BUYER TRUTH**
A computationally verified P-01 technology (conditional on geometry/scope) with physical validation still outstanding.

**EXECUTIVE PROPOSITION**
Technology: Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow redistribution maintaining dual safety invariants. Problem: Catheter obstruction causes 30-50% of shunt failures. $35-50K per revision surgery (SOURCE_DERIVED: HCUP/AHRQ)..

**BUYER PROBLEM**
Who: Shunt OEM (Medtronic, Integra, Sophysa)
Problem: Catheter obstruction causes 30-50% of shunt failures. $35-50K per revision surgery (SOURCE_DERIVED: HCUP/AHRQ).
Current solution: Single-segment programmable valve (Medtronic Strata) — reactive, not predictive

**TECHNOLOGY**
Multi-segment CSF shunt with Bayesian occlusion prediction and pre-emptive flow redistribution maintaining dual safety invariants

**EVIDENCE LEDGER** (structured atoms — no blending)
  COMPUTATIONALLY_SUPPORTED:
    - claim: T2-CONDITIONAL. svMultiPhysics 3D Navier-Stokes verified 1D model within 16% on candidate geometry (flow-rate proxy). 22
      scope: external computational solver execution
      limitation: computational only — no physical validation
  MODELLED:
    - claim: 30% revision rate reduction
      scope: internal computational model
      limitation: model prediction — not experimentally verified
    - claim: $124M/yr value
      scope: internal computational model
      limitation: model prediction — not experimentally verified
    - claim: 24h survival (both designs fail ~14h)
      scope: internal computational model
      limitation: model prediction — not experimentally verified
  ASSUMED:
    - claim: FAILED ASSUMPTION: Strict dual-invariant FALSIFIED (peak 22>20 mmHg)
      scope: hostile attack or model test
      limitation: this assumption broke — buyer must not rely on it
    - claim: FAILED ASSUMPTION: 24h survival not achieved
      scope: hostile attack or model test
      limitation: this assumption broke — buyer must not rely on it
    - claim: FAILED ASSUMPTION: FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)
      scope: hostile attack or model test
      limitation: this assumption broke — buyer must not rely on it

**STRONGEST ALTERNATIVE**
Single-segment programmable valve (Medtronic Strata) — reactive, not predictive

**KNOWN FAILURES**
  - Strict dual-invariant FALSIFIED (peak 22>20 mmHg)
  - 24h survival not achieved
  - FDA nozzle benchmark 72% disagreement (different geometry, not P-01's)

**REMAINING UNCERTAINTY**
Whether multi-segment advantage survives a TRUE 3D multi-segment mesh (not flow-rate proxy). Implantable flow sensor doesn't exist commercially.

**DECISIVE EXPERIMENT**
  Experiment: V0 bench prototype: 4-segment shunt + COTS sensors + Arduino. 30 obstruction scenarios. Measure multi vs single peak ICP.
  Pass: Multi-segment peak ICP < single-segment in >=80% of scenarios
  Fail: Multi-segment shows no advantage over single-segment
  Cost: $3-5K (ESTIMATED: COTS components)
  Timeline: 3-6 months (ESTIMATED)

**REGULATORY STATUS**
PMA required (Class III implantable)

**COMMERCIAL ROUTE**
License to shunt OEM

**IP / DILIGENCE STATUS**
  BUYER_DILIGENCE_REQUIRED — no patent search performed
  Full freedom-to-operate analysis by buyer counsel
  (We are not running a patent court.)

**BUYER'S NEXT ACTION**
LICENSE — reproduce computation (clone, run svMultiPhysics), then commission V0 bench prototype
  BUYER_ACTION_ID: P01-EXP-001

**VALIDATION RESULTS** (computed by independent validator, not generator)
  Q1 (send without verbal): PASS
  Q2 (identify next step): PASS
  Q3 (facts vs hypotheses): PASS
  Q4 (challenge without trusting): PASS
  Errors: NONE

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━